Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Aducanumab Update for August 3, 2021

8/3/2021

 
All seven members of the FDA Peripheral and Central Nervous System Drugs Advisory Committee (AdComm), which reviewed and rejected aducanumab, published a Perspective in NEJM that questioned the criteria used to justify approval of aducanumab. The AdComm pointed out that approval was based on a reduction of beta-amyloid that was measured through positron-emission tomographic brain imaging. The committee found available clinical evidence from trials to not support lowered beta-amyloid as a prediction of clinical benefit. The AdComm did not find a single positive study as justification for clinical benefit. They also reiterate the FDA’s statistical review of EMERGE and ENGAGE failed to find evidence that amyloid changes correlated with cognitive or functional changes. Aducanumab labeling does not require verification of elevated beta-amyloid despite the FDA basing approval on beta-amyloid reduction. This becomes an important issue since almost half of patients with mild cognitive impairment that are being assessed for Alzheimer’s disease do not have elevated levels of beta-amyloid.
 
Four FDA officials involved in the approval of aducanumab supplied a rebuttal to the Peripheral and Central Nervous System Drugs Advisory Committee Perspective in NEJM in the same issue of the journal. The FDA officials argue that use of beta-amyloid as a surrogate marker was justified due to more recent studies demonstrating that larger decrease in amyloid plaque correlates with the effect on clinical end points. They point out that while earlier studies of amyloid reducing drugs did not demonstrate a clinical benefit, the products used had little or no effects on amyloid plaque. The decision to approve aducanumab under an Accelerated Approval was justified because they judged the drug to be “reasonably likely” to predict clinical benefit”. There was no explanation for approval without requiring establishment of amyloid plaque nor the reason for disagreeing with the FDA Biostatistical Review. Data that supports a beneficial response in relation to plaque reduction is not currently published.
 
We have updated our review of aducanumab and the revised report can be downloaded on our sample drug review web page. In addition to the information above, we have added live links for all references in our review.
 
Our mission at Prescribe Right is to offer budget-friendly products that provide the information you need to proactively plan for budget-busting drugs. Due to the financial pressure from the pandemic, we are offering a new reduced rate to help keep our subscribers financially healthy. OUR NEW LOWER annual subscription for all searching functionality to our comprehensive, unbiased, verifiable knowledgebase is $675 and includes access to our New Drug Reviews for drugs with PDUFA dates.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.